ugichem Receives €2.25 Million funding for Antisense Drug Platform
News May 29, 2013
Based on its proprietary Ugimer platform ugichem aims to develop a pipeline of antisense drugs addressing unmet medical needs in indications involving inflammatory processes with a current focus on rheumatoid arthritis.
With a new in vivo efficacy and safety profile the Ugimer antisense drug platform enables the functional modification of disease-relevant, previously undruggable targets in tissues and cells of the immune system not amenable to standard antisense approaches and RNAi. Ugimers penetrate immune cells, such as T cells, without the need for additional delivery tools and do not stimulate the immune system resulting in reduced side effects and an improved safety profile. Recent preclinical data using Ugimers demonstrated a highly efficacious modulation of target mRNAs and, consequentially, a significant reduction of inflammatory cytokines after endotoxemia in vivo in various key tissues for inflammatory disease including the spleen and thymus.
Dr Holger Bock, CEO of ugichem, said: “During the past two years we have generated significant evidence to support our unique antisense platform. Ugimers enable the utilization of the powerful antisense mechanism to modulate previously undruggable targets in inflammation. The additional funding will be used to further build on the therapeutic value of Ugimers and will allow us to identify lead candidates in acute and chronic inflammation.”
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE
Genetics Help Make a Weed a WeedNews
A study has has found that the success of weedy and invasive plants like the Jerusalem artichoke lies in their genes. Understanding how invasive plants evolve and the genes that enable them to thrive in a new environment is key to better understanding why they are wreaking havoc on natural landscapes and food production around the world.READ MORE